ID: h-9553243b
Hypothesis
Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound
Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 5 oppose
🧪 Overview
Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Focused Ultrasound<br/>Blood-Brain Barrier Opening"]
B["Anti-Amyloid Antibody<br/>Enhanced Delivery"]
C["Network-Level Amyloid<br/>Clearance Achieved"]
D["Functional Connectivity<br/>Restoration"]
E["Transcranial Targeting<br/>Precision Delivery"]
F["AD Pathology Reduction<br/>at Network Scale"]
G["FUS as Amyloid<br/>Immunotherapy Adjuvant"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"enables"| B
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports5 contradicts
Supports
Hub regions show preferential amyloid deposition due to high activity-dependent amyloid production
Supports
Network-level degeneration in AD follows connectivity patterns - hubs are vulnerable
Supports
Exablate Neuro FDA-approved for essential tremor/PD - regulatory pathway exists
Contradicts
tFUS spatial precision limited to 2-5mm - sub-centimeter hub targeting unachievable
Contradicts
Even robust amyloid clearance (lecanemab/donanemab) produces only 27-35% clinical slowing
Contradicts
FcRn-mediated IgG recycling provides substantial brain penetration without tFUS
Contradicts
40-60% enhancement prediction lacks empirical basis - unsubstantiated numerical claim
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NETWORK-DIRECTED
No curated PDB or AlphaFold mapping for NETWORK-DIRECTED yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for Network-Directed Anti-Amyloid Immunotherapy.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.9%
Volatility
Medium
0.0206
Events (7d)
2
Price History
▲34.5%💾 Resource Usage
LLM Tokens
47,826
$0.1435
Total Cost
$0.1435
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF network-directed transcranial focused ultrasound (tFUS) is applied to the default mode network in early Alzheimer's disease patients receiving standard anti-amyloid antibody therapy (e.g., lecanema | ≥15% reduction in DMN amyloid PET standardized uptake value ratio (SUVR) relative to baseline, with ≥10% differential reduction compared to non-targeted cortica | — no observation — | pending | 0.65 |
| IF network-directed tFUS preferentially enhances anti-amyloid antibody delivery across the blood-brain barrier in Alzheimer's disease patients, THEN cerebrospinal fluid (CSF) amyloid-beta 42/40 ratio | CSF Aβ42/40 ratio increase of ≥0.05 units in tFUS + immunotherapy group vs. ≥0.02 units in immunotherapy-only group (demonstrating enhanced amyloid clearance). | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF network-directed transcranial focused ultrasound (tFUS) is applied to the default mode network in early Alzheimer's disease patients receiving standard anti-amyloid antibody therapy (e.g., lecanemab or donanemab), THEN amyloid burden measured by PiB or florbetapir PET will show significantly grea
Predicted outcome: ≥15% reduction in DMN amyloid PET standardized uptake value ratio (SUVR) relative to baseline, with ≥10% differential reduction compared to non-target
Falsification: No statistically significant difference in amyloid reduction between tFUS-targeted and non-targeted brain regions (p>0.05, two-tailed t-test), or amyloid increased/unchanged in targeted regions.
pendingconf 55%
IF network-directed tFUS preferentially enhances anti-amyloid antibody delivery across the blood-brain barrier in Alzheimer's disease patients, THEN cerebrospinal fluid (CSF) amyloid-beta 42/40 ratio will show greater improvement in the tFUS + immunotherapy group compared to immunotherapy alone with
Predicted outcome: CSF Aβ42/40 ratio increase of ≥0.05 units in tFUS + immunotherapy group vs. ≥0.02 units in immunotherapy-only group (demonstrating enhanced amyloid cl
Falsification: No significant difference in CSF Aβ42/40 ratio between groups, or worsening of the ratio in the tFUS group, indicating failed or reversed amyloid clearance.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.